Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | Director | June 11, 2026 | June 16, 2026 |
| Verastem, Inc.VSTM · Entity 5242 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PUMA BIOTECHNOLOGY, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 113,858 |
Ending reported balance
After 2026-06-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-11 · Grant · Acquired 27,000 · Balance 121,958 F1: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Row 2 · 2026-06-12 · Sale · Disposed 8,100 · Balance 113,858 F2: Adoption date of referenced 10b5-1(c) plan is: 03-12-2025 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.
F2: Adoption date of referenced 10b5-1(c) plan is: 03-12-2025
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Verastem, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 137,147 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 36,000 · Balance 137,147 F1: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 16, 2026 00:14 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 8,100 | $7.20 | $58,311.09 |
DisclosureSEC source: 0001437749-26-020708 · rdgdoc.xml · nonDerivative · entry 2 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,858 F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 03-12-2025 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 00:14 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-020708 · rdgdoc.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,958 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 21, 2026 Filed May 26, 2026 22:22 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-066424 · tm2615478-1_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,147 F1 · shares: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:47 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 592 | $9.14 | $5,410.88 |
DisclosureSEC source: 0001104659-25-122579 · tm2533899-3_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,147 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 22:16 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 587 | $9.99 | $5,864.13 |
DisclosureSEC source: 0001104659-25-091362 · tm2526484-3_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,739 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 16, 2025 Filed Jun 20, 2025 15:21 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 594 | $5.65 | $3,356.10 |
DisclosureSEC source: 0001104659-25-061039 · tm2518337-1_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,326 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 23:52 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 8,100 | $3.39 | $27,459.00 |
DisclosureSEC source: 0001437749-25-020719 · rdgdoc.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,958 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 03/12/2025 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.34 to $3.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 11, 2025 Filed Jun 14, 2025 00:12 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-020359 · rdgdoc.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,058 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:46 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001104659-25-053099 · tm2516118-6_4seq1.xml · derivative · entry 2 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-05-22 F2 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:46 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-053099 · tm2516118-6_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,920 F1 · shares: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:46 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 593 | $6.95 | $4,121.35 |
DisclosureSEC source: 0001104659-25-025608 · tm259809-1_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,587 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:31 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 334 | $4.37 | $1,459.58 |
DisclosureSEC source: 0001104659-24-130847 · tm2431760-2_4seq1.xml · nonDerivative · entry 2 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,180 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| December 16, 2024 Filed Dec 20, 2024 21:31 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 595 | $4.54 | $2,701.30 |
DisclosureSEC source: 0001104659-24-130847 · tm2431760-2_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,514 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 22:00 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 336 | $2.79 | $937.44 |
DisclosureSEC source: 0001104659-24-101764 · tm2424483-1_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,109 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 20:30 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 600 | $2.80 | $1,680.00 |
DisclosureSEC source: 0001104659-24-100988 · tm2424302-2_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,445 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 00:27 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 335 | $3.21 | $1,075.35 |
DisclosureSEC source: 0001104659-24-073600 · tm2417704-1_4seq1.xml · nonDerivative · entry 3 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,045 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units ("RSUs"). Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:27 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001104659-24-073600 · tm2417704-1_4seq1.xml · derivative · entry 4 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-18 F3 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:27 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073600 · tm2417704-1_4seq1.xml · nonDerivative · entry 2 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,380 F2 · shares: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 18, 2024 Filed Jun 22, 2024 01:25 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-021022 · rdgdoc.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,058 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 17, 2024 Filed Jun 21, 2024 00:27 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 593 | $3.49 | $2,069.57 |
DisclosureSEC source: 0001104659-24-073600 · tm2417704-1_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,047 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units ("RSUs"). Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 23:25 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 9,900 | $3.39 | $33,528.33 |
DisclosureSEC source: 0001437749-24-020572 · rdgdoc.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,058 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-16-2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.3001 to $3.5401, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 21:32 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 273 | $10.38 | $2,833.74 |
DisclosureSEC source: 0001104659-24-036787 · tm249354-1_4seq1.xml · nonDerivative · entry 2 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,640 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:32 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 537 | $10.71 | $5,751.27 |
DisclosureSEC source: 0001104659-24-036787 · tm249354-1_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,913 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:17 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 11,865 | Not disclosed Strike: $11.44 | Not disclosed |
DisclosureSEC source: 0001104659-24-034044 · tm248737-7_4seq1.xml · derivative · entry 3 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,865 Underlying: Common Stock · 11,865 shares Expires 2034-03-11 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 12,572 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F1 · derivative.exercise_date: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 12,572 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:17 UTC | Verastem, Inc. VSTM · Entity 5242 | Disposition to issuerStock Option (right to buy) · Derivative | 7,699 | Not disclosed Strike: $21.72 | Not disclosed |
DisclosureSEC source: 0001104659-24-034044 · tm248737-7_4seq1.xml · derivative · entry 2 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2029-06-21 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 12,572 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F3 · derivative.exercise_date: The canceled stock option was granted on June 21, 2019 and provided for vesting in twelve equal monthly installments beginning on July 21, 2019 and ending on June 21, 2020. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:17 UTC | Verastem, Inc. VSTM · Entity 5242 | Disposition to issuerStock Option (right to buy) · Derivative | 4,166 | Not disclosed Strike: $59.04 | Not disclosed |
DisclosureSEC source: 0001104659-24-034044 · tm248737-7_4seq1.xml · derivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,157 shares Expires 2028-06-11 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange, the Reporting Person received a grant of 12,572 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F2 · derivative.exercise_date: The canceled stock option was granted on June 21, 2018 and provided for vesting in twelve equal monthly installments beginning on October 2, 2017 ending on September 2, 2018. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:00 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 274 | $7.73 | $2,118.02 |
DisclosureSEC source: 0001104659-23-127723 · tm2333364-1_4seq1.xml · nonDerivative · entry 2 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,450 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:00 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 487 | $7.64 | $3,720.68 |
DisclosureSEC source: 0001104659-23-127723 · tm2333364-1_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,724 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 20:15 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 274 | $9.84 | $2,696.16 |
DisclosureSEC source: 0001104659-23-102296 · tm2326467-1_4seq1.xml · nonDerivative · entry 2 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,211 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:15 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 478 | $9.91 | $4,736.98 |
DisclosureSEC source: 0001104659-23-102296 · tm2326467-1_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,485 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 20:23 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 275 | $10.30 | $2,832.50 |
DisclosureSEC source: 0001104659-23-073360 · tm2319280-1_4seq1.xml · nonDerivative · entry 2 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,963 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:23 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 487 | $9.92 | $4,831.04 |
DisclosureSEC source: 0001104659-23-073360 · tm2319280-1_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,238 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 01:06 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-017608 · rdgdoc.xml · nonDerivative · entry 2 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,958 F3 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 01:06 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 9,900 | $3.46 | $34,252.02 |
DisclosureSEC source: 0001437749-23-017608 · rdgdoc.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,958 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-15-2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.43 to $3.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 20:54 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 3,508 | $0.43 | $1,508.44 |
DisclosureSEC source: 0001104659-23-034507 · tm239927-1_4seq1.xml · nonDerivative · entry 2 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,112,736 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 20:54 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 6,276 | $0.40 | $2,510.40 |
DisclosureSEC source: 0001104659-23-034507 · tm239927-1_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,116,244 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:06 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 2,216,355 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001104659-23-008595 · tm234891-3_4seq1.xml · derivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,216,355 Underlying: Common Stock · 2,216,355 shares Expires 2033-01-27 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of January 27, 2023 (the "Grant Date") and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the Grant Date until the fourth anniversary of the Grant Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| December 19, 2022 Filed Dec 20, 2022 21:09 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 3,556 | $0.37 | $1,315.72 |
DisclosureSEC source: 0001104659-22-128638 · tm2233121-1_4seq1.xml · nonDerivative · entry 2 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,122,520 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:09 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 25,162 | $0.40 | $10,064.80 |
DisclosureSEC source: 0001104659-22-128638 · tm2233121-1_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,126,076 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:07 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 3,355 | $1.13 | $3,791.15 |
DisclosureSEC source: 0001104659-22-101926 · tm2226273-3_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151,238 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 20:07 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 5,858 | $1.08 | $6,326.64 |
DisclosureSEC source: 0001104659-22-085179 · tm2222296-1_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,154,593 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 20:06 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 3,362 | $1.14 | $3,832.68 |
DisclosureSEC source: 0001104659-22-073483 · tm2219034-2_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,160,451 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 23:09 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 13,000 | $2.69 | $34,918.00 |
DisclosureSEC source: 0001437749-22-015527 · rdgdoc.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,858 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.614 to $2.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 00:04 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-015215 · rdgdoc.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,858 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 16, 2022 Filed May 17, 2022 20:07 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 13,794 | $1.03 | $14,207.82 |
DisclosureSEC source: 0001104659-22-061938 · tm2215781-2_4seq1.xml · nonDerivative · entry 2 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,163,813 F2 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| May 14, 2022 Filed May 17, 2022 20:07 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-061938 · tm2215781-2_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,177,607 F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted to the Reporting Person on June 24, 2021 under the Issuer's 2021 Equity Incentive Plan. Each PRSU represents the right to receive one share of Common Stock. On May 14, 2022 the Compensation Committee of the Issuer's Board of Directors certified that the PRSUs' performance criteria had been satisfied and the PRSUs vested in full. Read SEC document |
| May 02, 2022 Filed May 4, 2022 20:00 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 5,857 | $1.41 | $8,258.37 |
DisclosureSEC source: 0001104659-22-055810 · tm2214465-1_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,127,607 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:01 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 3,507 | $1.27 | $4,453.89 |
DisclosureSEC source: 0001104659-22-037007 · tm2210137-3_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,133,464 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:05 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 5,695 | $1.48 | $8,428.60 |
DisclosureSEC source: 0001104659-22-010827 · tm225212-1_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,136,971 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:03 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 26,033 | $2.05 | $53,367.65 |
DisclosureSEC source: 0001104659-22-001451 · tm221611-3_4seq1.xml · nonDerivative · entry 1 Stuglik Brian M · CIK 0001716328 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,142,666 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.